Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Overview of Gastric Cancer Prevention Initiatives in Europe.

Helicobacter·2026

Same author

What Is New in the German S3 Guideline on Gastric Cancer: Diagnosis, Staging, and Treatment.

Oncology research and treatment·2026

Same author

Regular arrangement of collecting venules as a predictor of <i>Helicobacter pylori</i> absence using white-light endoscopy: a multicenter prospective study outside Asia.

Therapeutic advances in gastrointestinal endoscopy·2025

Same author

Author Correction: Spatial fibroblast niches define Crohn's fistulae.

Nature·2025

Same author

The Disease Burden of Helicobacter pylori Beyond Gastric Cancer: Quantifying the Forgotten Potential Benefits of Mass Eradication.

Gastroenterology·2025

Same author

Spatial fibroblast niches define Crohn's fistulae.

Nature·2025

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of ⁶⁸Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Octreotide LAR: safety and tolerability issues.

Jan Bornschein¹, Ignat Drozdov, Peter Malfertheiner

¹Otto-von-Guericke University of Magdeburg, Department of Gastroenterology, Hepatology and Infectious Diseases, Germany.

Expert Opinion on Drug Safety

|December 10, 2009

Summary

This summary is machine-generated.

Octreotide LAR is a well-tolerated treatment for acromegaly and neuroendocrine tumors. Common side effects include diarrhea and gallstones, with unpredictable glucose level changes.

Related Experiment Videos

Last Updated: Jun 17, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of ⁶⁸Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Area of Science:

Endocrinology
Pharmacology

Background:

Somatostatin analogues are key treatments for acromegaly and neuroendocrine tumors.
Long-acting formulations like octreotide LAR have improved patient outcomes and quality of life.
Octreotide LAR targets somatostatin receptor subtypes 2 and 5, administered via intramuscular injection every 4 weeks.

Purpose of the Study:

To comprehensively review the literature on octreotide LAR.
To evaluate the safety and tolerability profile of octreotide LAR.

Main Methods:

An extensive literature search was conducted using the MEDLINE database.
Data from clinical studies on octreotide LAR efficacy and tolerability were retrieved and analyzed.

Main Results:

Octreotide LAR is generally well tolerated.
Diarrhea and gallstone formation are the primary adverse events.
Impaired glucose homeostasis is a common but unpredictable side effect.

Conclusions:

Octreotide LAR demonstrates good tolerability, with diarrhea and gallstones as main adverse events.
While generally safe, further evidence is needed regarding pregnancy use.
Ongoing research into newer compounds like lanreotide and SOM230 aims to enhance efficacy and reduce side effects.